Literature DB >> 8142643

Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma.

F Lo Coco1, B H Ye, F Lista, P Corradini, K Offit, D M Knowles, R S Chaganti, R Dalla-Favera.   

Abstract

The pathogenesis of non-Hodgkin's lymphoma (NHL) with a large cell component (DLLC, including diffuse large cell, DLCL; diffuse mixed cell, MX-D; and immunoblastic, IMB) is unknown. A novel candidate proto-oncogene, BCL6, that is involved in chromosome band 3q27 aberrations in NHL has been recently identified. We have investigated the incidence and disease-specificity of BCL6 rearrangements in a large panel of lymphoid tumors, including acute and chronic lymphoid leukemias (96 cases), various NHL types (125 cases), and multiple myelomas (23 cases). BCL6 rearrangements were found in 16/45 (35.5%) DLLC, more frequently in DLCL (15/33, 45%) than in MX-D (1/10, 10%), in 2/31 (6.4%) follicular NHL, and in no other tumor types. BCL6 rearrangements represent the first genetic lesion specifically and recurrently associated with DLLC and should prove useful for understanding the pathogenesis as well as for the clinical monitoring of these tumors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8142643

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  57 in total

Review 1.  Molecular diagnostic approach to non-Hodgkin's lymphoma.

Authors:  D A Arber
Journal:  J Mol Diagn       Date:  2000-11       Impact factor: 5.568

Review 2.  Epigenetic therapy of lymphoma using histone deacetylase inhibitors.

Authors:  Maribel Cotto; Fernando Cabanillas; Maribel Tirado; María V García; Eileen Pacheco
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

3.  Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component.

Authors:  Tiemo Katzenberger; German Ott; Thomas Klein; Jörg Kalla; Hans Konrad Müller-Hermelink; M Michaela Ott
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

4.  Quantitative modeling of the terminal differentiation of B cells and mechanisms of lymphomagenesis.

Authors:  María Rodríguez Martínez; Alberto Corradin; Ulf Klein; Mariano Javier Álvarez; Gianna M Toffolo; Barbara di Camillo; Andrea Califano; Gustavo A Stolovitzky
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

5.  BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor.

Authors:  C C Chang; B H Ye; R S Chaganti; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

6.  Somatic mutation of the 5' noncoding region of the BCL-6 gene is associated with intraclonal diversity and clonal selection in histological transformation of follicular lymphoma.

Authors:  Z Szereday; B Csernus; M Nagy; T László; R A Warnke; A Matolcsy
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

7.  Detection of the bcl-2 t(14;18) translocation and proto-oncogene expression in primary intraocular lymphoma.

Authors:  Dana J Wallace; DeFen Shen; George F Reed; Masaru Miyanaga; Manabu Mochizuki; H Nida Sen; Samuel S Dahr; Ronald R Buggage; Robert B Nussenblatt; Chi-Chao Chan
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-07       Impact factor: 4.799

Review 8.  Nodal aggressive B-cell lymphomas: a diagnostic approach.

Authors:  Sonam Prakash; Steven H Swerdlow
Journal:  J Clin Pathol       Date:  2007-03-16       Impact factor: 3.411

9.  De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct.

Authors:  A Matolcsy; A Chadburn; D M Knowles
Journal:  Am J Pathol       Date:  1995-07       Impact factor: 4.307

10.  High levels of bcl-2 protein expression do not correlate with genetic abnormalities but predict worse prognosis in patients with lymphoblastic lymphoma.

Authors:  Yajun Gu; Yi Pan; Bin Meng; Bingxin Guan; Kai Fu; Baocun Sun; Fang Zheng
Journal:  Tumour Biol       Date:  2013-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.